AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a ...
The health sector is witnessing crucial developments including US turkey flu testing advocacy, WHO lobbying to retain US membership, and Medicare price negotiations involving major drugs. Meanwhile, ...
Against a backdrop of rising U.S.-China geopolitical tensions, there are signs of growing dealmaking activity between Western ...
Our writer reckons this tech-driven FTSE 250 investment trust has what it takes to outperform Rolls-Royce shares between now ...
AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront. The compound – called UA022 – targets the ...